Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Retained Earnings: 2021-2024

Historic Retained Earnings for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to -$1.1 billion.

  • Autolus Therapeutics' Retained Earnings fell 20.98% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 20.98%. This contributed to the annual value of -$1.1 billion for FY2024, which is 25.12% down from last year.
  • Autolus Therapeutics' Retained Earnings amounted to -$1.1 billion in FY2024, which was down 25.12% from -$878.6 million recorded in FY2023.
  • Autolus Therapeutics' 5-year Retained Earnings high stood at -$521.3 million for FY2021, and its period low was -$1.1 billion during FY2024.
  • In the last 3 years, Autolus Therapeutics' Retained Earnings had a median value of -$878.6 million in 2023 and averaged -$882.7 million.
  • Data for Autolus Therapeutics' Retained Earnings shows a maximum YoY plummeted of 31.09% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Retained Earnings stood at -$521.3 million in 2021, then decreased by 28.55% to -$670.2 million in 2022, then plummeted by 31.09% to -$878.6 million in 2023, then fell by 25.12% to -$1.1 billion in 2024.